Programme
Sunday 3 November 2024 | ||||
---|---|---|---|---|
Time |
HALL 4 |
HALL 5 |
HALL 6 |
HALL 7 |
13:00 – 15:00 |
IS1 |
IS2 |
IS3 |
IS4 |
Building an Antimicrobial Stewardship Programme: Challenges and Achievements |
ISAC / ICC Early Career Scientist Workshop |
"From bench to bedside" |
Organised by the ISAC Infection Prevention & Control Working Group |
|
Chair: Building the ASP in a Turkish Referral Hospital Insights from a resource rich setting Building an Antimicrobial Stewardship Programme: what is the evidence |
Chair: Surface Interactions and Mechanical Properties Shaping Biofilm Dynamics in S. aureus and P.aeruginosa Vital Signs or Lab parameters: Evaluation of National Early Warning Score2(NEWS2) and Sequential Organ Failure Assessment (SOFA) Scores for Sepsis screening in Low resource hospital setting Context-specific impact of antimicrobial stewardship on antibiotic use and antibiotic resistance in hospitals in a lower-middle income country – results from implementation study with a controlled interrupted time series design in Vietnam Role of Nocardia sp. bioactives in regulating the key molecular checkpoints in quorum-sensing pathways P. aeruginosa: application towards improved fabrication of medical devices Identifying Risk Factors for Surgical Site Infections Following Posterior Cervical Laminectomy: A Comprehensive Analysis Using ACS NSQIP Data Bassem Awada Analysis of imported malaria cases: 5 years of experience Antimicrobial Resistance in Coagulase Negative Staphylococci: Genome Analysis and Role of Horizontal Gene Transfer |
Chair: Basics of antibiotic pharmacokinetics / pharmacodynamics Use of in vitro and in vivo models to elucidate the PK/PD driver of antimicrobial activity Optimising antibiotic treatment in patients using PK/PD |
Chair: Do we really need those gloves? Gowns and respiratory viruses Scrub, scrub, scrub… which surfaces and why should be disinfected |
|
15:00 – 15:30 |
Coffee |
|||
15:30 – 17:30 |
IS5 |
IS6 |
IS7 |
IS8 |
Getting Your Paper Published: What You Need to Know as an Author Organised in collaboration with Elsevier |
"From bench to bedside" |
|||
Chair: Is broad spectrum antibiotics always necessary for patients admitted with sepsis to ICU? Antibiotic de-escalation in the ICU The value of clinical microbiology to guide treatment for infectious diseases in the ICU |
Chair: Overview of the latest developments in the publishing industry / How to get published What Editors Look For: Insights from the Journal of Global Antimicrobial Resistance Editor-in-Chief What Editors Look For: Insights from an Editor of the International Journal of Antimicrobial Agents |
Chairs: Standardisation of antimicrobial susceptibility testing – Where are we? Obstacles and challenges in implementation of EUCAST methodology (and how to overcome them) What to do when there are no breakpoints in the EUCAST table? |
Chair: Facilitators: 1. Welcome and introduction |
|
HALL 1 | ||||
17:30 – 18:30 |
Opening A Tribute to Professor Alasdair Geddes |
|||
18:30 – 19:30 |
Chair: Souha Kanj ISAC’s Hamao Umezawa Memorial Award (HUMA) |
|||
19:30-20:30 | Opening Reception |
Monday 4 November 2024 | |||
---|---|---|---|
Time |
HALL 1 |
HALL 2 |
HALL 3 |
09:00 – 09:45 |
Plenary Lecture 2 |
||
Chair: mRNA Vaccine Platform Today and Tomorrow |
|||
09:45 – 10:15 |
Coffee and Exhibition |
||
10:15- 11:45 |
SY 1 |
SY 2 |
SY 3 |
Artificial Intelligence in Anti-infectives Organised in collaboration with ISAC Anti-infective Pharmacology Working Group |
Bacteriophage therapy: Where are we now? Organised in collaboration with Anti-infective Pharmacology Working Group and the International Society for Anti-infective Pharmacology (ISAP) |
Changing paradigms and new approaches in clinical microbiological diagnosis |
|
Chairs: Tracking antibiotic resistance with artificial intelligence Optimising antibiotic use with model-informed precision dosing Treating infectious diseases with machine-learning based prediction models |
Chairs: Phage pharmacokinetics: Why does it matter? Phage therapy: How to build a bridge between researchers and clinicians? Personalised phage therapy: Where are we now? |
Chairs: Biomarkers, emergency admission and triaging: recognising the ill looking well and the well looking ill Syndromic Diagnostic Tests: New approach in microbiological diagnosis Impact of NGS-assisted diagnostics on the diagnosis of infectious diseases |
|
11:45 – 13:15 |
Industry Symposium Tackling AMR in CA-RTIs: optimising outcomes with evidence-based decision making 11:45–11:55 11:55–12:10 12:10–12:20 12:20–12:35 12:35–12:45 12:45–13:00 13:00–13:05 13:05–13:15 |
Meet The Experts- Updates on prevention and management of the Respiratory Infections 11:45-11:50 11:50- 12:25 12:25- 13:00 13:00- 13:15 |
|
13:15 – 14:45 |
SY 4 |
SY 5 |
SY 6 |
HIV prevention, inflammation and metabolic disorders |
Emerging and Reemerging Infections among Migrants Organised in collaboration with Cyprus Society of Clinical Microbiology and Infectious Diseases |
Antimicrobial stewardship in critical care units Organised in collaboration with the ISAC ICU and Sepsis Working Group |
|
Chairs: HIV prevention current situation and beyond Lipid disorders in people living with HIV Is there a chance to control chronic inflammation |
Chairs: A United Front: Global Collaboration to Combat AMR through One Health Group A streptococci, Diphtheriae and other bacterial vaccine-preventable infections in refugees Outbreaks in conflicts: the case of leishmania |
Chairs: Influencing beyond your authority: antimicrobial stewardship in critical care patients Antibiotic de-escalation in the ICU : is it worth it ? Pauze or continue- treatment options for antibacterial agents |
|
14:45 – 15:45 |
Coffee / Poster Session 1 |
||
15:45 – 16:30 |
Plenary Lecture 3 |
||
Chair: Infectious diseases and wars: past and present |
|||
16:30-17:00 |
KN 1 |
KN 2 |
|
Chair:
Averting the antimicrobial resistance crisis: barriers to effective antimicrobial stewardship |
Chair: Antimicrobial Collateral Risk on Microbiota |
Tuesday 5 November 2024 | ||||
---|---|---|---|---|
Time |
HALL 1 |
HALL 2 |
HALL 3 |
HALL 4 |
09:30-10:00 |
KN 3 |
KN 4 |
|
|
Chair: Antimicrobial resistance and immunocompromised patients: Past Today and Tomorrow |
Chair: Infection control: where we came from and future challenges |
|
||
10:00 – 10:30 |
Coffee and Exhibition |
|||
10:30 – 12:00 |
SY 7 |
SY 8 |
SY 9 |
Oral Session 1 |
Diagnostic and Treatment Strategies for Infections Caused by High-Risk Gram negative bacteria |
The pandemic “goes away”, the real pandemic is here: Sepsis 2024 Organised in collaboration with the European Sepsis Alliance |
WHO Fungal priority pathogen list- Challenges in the diagnosis and management |
Chairs: Hakan Erdem David Jenkins |
|
Chair: Resistance and virulence features of hypermucoviscous Klebsiella pneumoniae from bloodstream infections Clinical Impact and Public Health Implications of High-Risk E. coli Clones Molecular Epidemiology and Global Spread of Hypervirulent Acinetobacter spp. and Pseudomonas spp. |
Chairs: Immune classification: the time has come Laboratory diagnosis (Biomarkers & molecular diagnostics) in sepsis – do they really help? Holistic patient management: does this exist? |
Chairs: Overview of the fungal priority pathogens Azole resistant Aspergillus fumigatus in clinics and environment: from screening to containment policy Emergence of spread of resistance in Candida species |
Click here for details |
|
12:00 – 13:30 |
Rapid Diagnostics & Targeted Antimicrobial Therapy in Sepsis Management. Welcoming and Introduction Nosocomial Pneumonia & Early Antimicrobial Therapy Sepsis: Strategies for Rapid Diagnosis & Management Panel Discussion (Q&A) |
Influenza vaccines: Why do we need protection beyond flu? Co-Chaired by Meral Akcay-Alireza Mafi 12:00-12:05 12:05- 12:30 12:30-13:00 13:00-13:30 |
||
13:30 – 15:30 | ESCMID Symposium | |||
Climate change and change in infections | ||||
Chairs: Change in infections Effects of climate change on AMR Rickettsial diseases Melioidosis |
||||
15:30 – 16:30 |
Coffee / Poster Session 2 |
|||
16:30 – 18:00 |
SY 10 |
SY 11 |
SY 12 |
ISI-R SYMPOSIUM |
Impact of the WHO National AMR action plans: Success stories Organised in collaboration with the Alliance for the Prudent Use of Antibiotics (APUA) |
How vaccines are changing the AMR landscape Organised in collaboration with the ISAC Immunisations & Vaccines Working Group |
Osteoarticular infections Organised in collaboration with the ISAC Rapid Diagnostics and Biomarkers Working Group |
Chairs:
Yasemin Çağ Heiman Wertheim |
|
Chairs: Success stories from Middle East ESCMID guidelines for antimicrobial stewardship in emergency departments Success stories from Asia |
Chairs: Antimicrobial resistance in the 21st century How vaccines have changed the AMR landscape so far in the 21st century Potential for further impacts on AMR from current and future vaccines |
Chairs: A multicentre evaluation and expert recommendations of use of the newly developed BioFire Joint Infection polymerase chain reaction panel Mycobacterial Prosthetic Joint infections Novel and Long acting anti gram positive antibiotics implication for bone and joint infections |
ID-IRI and its’ clinical research philosophy David Paterson |
Wednesday 6 November 2024 | ||||
---|---|---|---|---|
Time |
HALL 1 |
HALL 2 |
HALL 3 |
HALL 4 |
08:00 – 08:30 |
KN 5 |
KN 6 |
|
|
Chair: Pandemic Preparedness and Lessons Learnt |
Chair: Emerging Antifungal Resistance |
|||
08:30 – 09:15 |
Plenary Lecture 4 |
|||
Chair: Antimicrobial resistance in the 21st century |
||||
09:15 – 09:30 |
Coffee |
|||
09:30 – 11:00 |
SY 13 |
SY 14 |
SY 15 |
Oral Session 2 |
The built environment of the hospital and nosocomial infections; sources and transmission routes Organised in collaboration with the MRSA Working Group |
Antimicrobial resistance and one health Sponsored by the Japanese Society of Chemotherapy |
Advances in the diagnosis of mycobacteria and new risks for public health. |
Chairs: Ahmet Çağkan İnkaya Regina Berba |
|
Chairs: Acinetobacter species all around the ward; risks, causes and prevention Hospital design matters! The built environment of the hospital and infection prevention; lessons of the past pandemic, prepared for the future? |
Chairs: Antimicrobial resistance in animals The Climate-Resistance Nexus: Leveraging One Health to Combat Rising Antimicrobial Resistance Clinical significance of probiotics in controling antimicrobial resistance |
Chairs: Conventional and molecular diagnosis methods for rapid and accurate detection of TB: Old but gold? Update on diagnosis and treatment of M. abscessus infections Drug resistant tuberculosis among refugees and migrants |
Click here for details |
|
11:00 – 11:45 | Plenary Lecture 5 |
|||
Chair:
A Teleological View of Novel Molecular Diagnostics: Are We Adding Value or Confusion? |
||||
11:45 – 13:15 |
SY 16 |
SY 17 |
SY 18 |
Oral Session 3 |
Evidence based approach to AMR in hospitals Sponsored by the Asia Pacific Society of Clinical Microbiology & Infection (APSCMI) |
New Frontiers in so-called Untreatable Viral Infections |
Hot Topics in Hepatitis Organised in collaboration with the Viral Infections Working Group |
Chair: Özlem Kurt Azap, Oğuz Reşat Sipahi |
|
Chairs: Evidence based infection control of MDR gram negative bacteria Antimicrobial stewardship: clinical trial, modelling and qualitative studies Evidence base from randomised controlled trials in treatment of bacteraemia to combat AMR |
Chairs: Mechanisms of Latent Virus Activation in Immunocompromised Populations Advances in Treatment of Polyoma Virus Disease Antibodies against the infectious agents: Current challenges and opportunities |
Chairs: Retreatment of Chronic Hepatitis C patients failing first line regimens Hepatitis B virus vaccine; What is new? Emerging and re-emerging viruses and hepatic compromise |
Click here for details |